GOODRX TEAMS UP WITH VIATRIS TO PROVIDE UP TO 85% DISCOUNTS ON WELL-KNOWN BRAND MEDICATIONS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 hours ago
0mins
Should l Buy VTRS?
Source: moomoo
Partnership Announcement: GoodRx has partnered with Viatris to provide significant savings on established brand medications.
Savings Details: The collaboration offers up to 85% savings for consumers on select medications through GoodRx's platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to fall
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 14.080
Low
10.00
Averages
13.25
High
16.00
Current: 14.080
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GoodRx Partners with Viatris to Offer Up to 85% Discounts on Medications
- Discount Program Launch: GoodRx has partnered with Viatris to introduce a new program offering up to 85% discounts on 17 brand-name medications, including the cholesterol drug Lipitor, which is expected to significantly reduce patient medication costs.
- Extensive Coverage: The discount program will be available at over 70,000 pharmacies across the U.S., making it easier for patients to access necessary medications, thereby enhancing GoodRx's market position in drug price transparency and accessibility.
- Insurance Patient Benefits: Some Viatris medications will be available on GoodRx for as low as $0–$4 for patients with commercial insurance, a strategy that not only expands GoodRx's user base but may also improve patient adherence to medication regimens.
- Market Response: GoodRx noted that the selected medications already generate significant search volume on its platform, indicating strong market demand for these drugs, which further solidifies GoodRx's influence in the healthcare sector.
See More
GOODRX TEAMS UP WITH VIATRIS TO PROVIDE UP TO 85% DISCOUNTS ON WELL-KNOWN BRAND MEDICATIONS
Partnership Announcement: GoodRx has partnered with Viatris to provide significant savings on established brand medications.
Savings Details: The collaboration offers up to 85% savings for consumers on select medications through GoodRx's platform.
See More
Alphabet and Others Set for Ex-Dividend Dates
- GOOG Ex-Dividend Info: Alphabet Inc will go ex-dividend on March 9, 2026, with a quarterly dividend of $0.21, translating to an approximate yield of 0.07% based on its current stock price of $303.45, suggesting a potential 0.07% drop at market open, which could influence short-term investor decisions.
- CEG Dividend Announcement: Constellation Energy Corp will pay a quarterly dividend of $0.4265 on March 20, 2026, with an expected price drop of 0.13% post-ex-dividend, reflecting the company's efforts in maintaining stable dividends, potentially attracting yield-seeking investors.
- VTRS Dividend Dynamics: Viatris Inc will distribute a quarterly dividend of $0.12 on March 18, 2026, with an anticipated 0.82% decline at market open, indicating the company's ongoing commitment to dividend payments, which may enhance its market appeal.
- Dividend History and Yields: Historical data shows an annualized yield of 0.28% for Alphabet, 0.53% for CEG, and a notable 3.26% for VTRS, providing investors with a basis for assessing future dividend stability, which could impact their investment strategies.
See More
Viatris Named Among Best Dividend Stocks for March
- Price Target Increase: UBS raised Viatris's price target from $18 to $20 while maintaining a Buy rating, indicating improvements in cost savings and growth outlook, despite a 5% drop in shares following earlier gains.
- Strong Financial Performance: Viatris reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion for 2025, demonstrating solid positioning for sustainable long-term growth, with the CEO highlighting 2026 as a pivotal growth year.
- Significant R&D Progress: The company achieved positive results in five Phase III studies, with key program enrollments progressing well and expected to complete by 2026, laying the groundwork for future product line expansions.
- Shareholder Returns and Cost Savings: Viatris returned over $1 billion to shareholders through dividends and share repurchases in the past year, while also anticipating $650 million in gross cost savings over three years, with a portion earmarked for growth investments.
See More
Bastion Asset Management Acquires Stake in Parsons
- New Investment Position: Bastion Asset Management disclosed a new position in Parsons by acquiring 128,186 shares in Q4 2025, with an estimated transaction value of $8.04 million, indicating a strategic focus on defense and infrastructure sectors.
- Significant Holding Proportion: Following this transaction, Parsons represents 4.44% of Bastion's $181.13 million reportable U.S. equity assets, highlighting its importance in the portfolio and the firm's preference for stable cash flow investments.
- Market Performance Analysis: As of February 5, 2026, Parsons shares were priced at $67.52, reflecting a 13% decline over the past year and underperforming the S&P 500 by 25.12 percentage points, suggesting market caution regarding its future growth prospects.
- Diversified Business Advantage: Parsons operates a dual-segment model in defense and infrastructure, ensuring that when defense spending contracts, infrastructure projects can compensate for revenue shortfalls, demonstrating resilience amid economic fluctuations.
See More
Bastion Asset Management Acquires $8M Stake in Parsons
- New Position Disclosure: On February 6, 2026, Bastion Asset Management disclosed a new position in Parsons (NYSE:PSN), acquiring 128,186 shares valued at approximately $8.04 million, indicating a strategic interest in defense and infrastructure sectors.
- Holding Proportion Analysis: Following this transaction, Parsons represents 4.44% of Bastion's portfolio, which totaled $181.13 million in reportable U.S. equity assets as of December 31, 2025, reflecting Bastion's preference for stable income investments.
- Market Performance Overview: As of February 5, 2026, Parsons shares were priced at $67.52, down 13% year-over-year, underperforming the S&P 500 by 25.12 percentage points, indicating market caution regarding its future growth prospects.
- Business Diversification: Parsons generates revenue from various sectors, particularly through contracts with the Pentagon, demonstrating its ability to maintain stable cash flow amidst economic fluctuations, making it suitable for investors seeking steady returns.
See More
GoodRx Partners with Viatris to Offer Up to 85% Discounts on Medications
- Discount Program Launch: GoodRx has partnered with Viatris to introduce a new program offering up to 85% discounts on 17 brand-name medications, including the cholesterol drug Lipitor, which is expected to significantly reduce patient medication costs.
- Extensive Coverage: The discount program will be available at over 70,000 pharmacies across the U.S., making it easier for patients to access necessary medications, thereby enhancing GoodRx's market position in drug price transparency and accessibility.
- Insurance Patient Benefits: Some Viatris medications will be available on GoodRx for as low as $0–$4 for patients with commercial insurance, a strategy that not only expands GoodRx's user base but may also improve patient adherence to medication regimens.
- Market Response: GoodRx noted that the selected medications already generate significant search volume on its platform, indicating strong market demand for these drugs, which further solidifies GoodRx's influence in the healthcare sector.
See More
GOODRX TEAMS UP WITH VIATRIS TO PROVIDE UP TO 85% DISCOUNTS ON WELL-KNOWN BRAND MEDICATIONS
Partnership Announcement: GoodRx has partnered with Viatris to provide significant savings on established brand medications.
Savings Details: The collaboration offers up to 85% savings for consumers on select medications through GoodRx's platform.
See More
Alphabet and Others Set for Ex-Dividend Dates
- GOOG Ex-Dividend Info: Alphabet Inc will go ex-dividend on March 9, 2026, with a quarterly dividend of $0.21, translating to an approximate yield of 0.07% based on its current stock price of $303.45, suggesting a potential 0.07% drop at market open, which could influence short-term investor decisions.
- CEG Dividend Announcement: Constellation Energy Corp will pay a quarterly dividend of $0.4265 on March 20, 2026, with an expected price drop of 0.13% post-ex-dividend, reflecting the company's efforts in maintaining stable dividends, potentially attracting yield-seeking investors.
- VTRS Dividend Dynamics: Viatris Inc will distribute a quarterly dividend of $0.12 on March 18, 2026, with an anticipated 0.82% decline at market open, indicating the company's ongoing commitment to dividend payments, which may enhance its market appeal.
- Dividend History and Yields: Historical data shows an annualized yield of 0.28% for Alphabet, 0.53% for CEG, and a notable 3.26% for VTRS, providing investors with a basis for assessing future dividend stability, which could impact their investment strategies.
See More
Viatris Named Among Best Dividend Stocks for March
- Price Target Increase: UBS raised Viatris's price target from $18 to $20 while maintaining a Buy rating, indicating improvements in cost savings and growth outlook, despite a 5% drop in shares following earlier gains.
- Strong Financial Performance: Viatris reported total revenue of $14.3 billion and adjusted EBITDA of $4.2 billion for 2025, demonstrating solid positioning for sustainable long-term growth, with the CEO highlighting 2026 as a pivotal growth year.
- Significant R&D Progress: The company achieved positive results in five Phase III studies, with key program enrollments progressing well and expected to complete by 2026, laying the groundwork for future product line expansions.
- Shareholder Returns and Cost Savings: Viatris returned over $1 billion to shareholders through dividends and share repurchases in the past year, while also anticipating $650 million in gross cost savings over three years, with a portion earmarked for growth investments.
See More
Bastion Asset Management Acquires Stake in Parsons
- New Investment Position: Bastion Asset Management disclosed a new position in Parsons by acquiring 128,186 shares in Q4 2025, with an estimated transaction value of $8.04 million, indicating a strategic focus on defense and infrastructure sectors.
- Significant Holding Proportion: Following this transaction, Parsons represents 4.44% of Bastion's $181.13 million reportable U.S. equity assets, highlighting its importance in the portfolio and the firm's preference for stable cash flow investments.
- Market Performance Analysis: As of February 5, 2026, Parsons shares were priced at $67.52, reflecting a 13% decline over the past year and underperforming the S&P 500 by 25.12 percentage points, suggesting market caution regarding its future growth prospects.
- Diversified Business Advantage: Parsons operates a dual-segment model in defense and infrastructure, ensuring that when defense spending contracts, infrastructure projects can compensate for revenue shortfalls, demonstrating resilience amid economic fluctuations.
See More
Bastion Asset Management Acquires $8M Stake in Parsons
- New Position Disclosure: On February 6, 2026, Bastion Asset Management disclosed a new position in Parsons (NYSE:PSN), acquiring 128,186 shares valued at approximately $8.04 million, indicating a strategic interest in defense and infrastructure sectors.
- Holding Proportion Analysis: Following this transaction, Parsons represents 4.44% of Bastion's portfolio, which totaled $181.13 million in reportable U.S. equity assets as of December 31, 2025, reflecting Bastion's preference for stable income investments.
- Market Performance Overview: As of February 5, 2026, Parsons shares were priced at $67.52, down 13% year-over-year, underperforming the S&P 500 by 25.12 percentage points, indicating market caution regarding its future growth prospects.
- Business Diversification: Parsons generates revenue from various sectors, particularly through contracts with the Pentagon, demonstrating its ability to maintain stable cash flow amidst economic fluctuations, making it suitable for investors seeking steady returns.
See More
